Latest & greatest articles for aids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aids

521. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group.

Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. 7637721 1995 09 14 1995 09 14 2013 11 21 0028-4793 333 10 1995 Sep 07 The New England journal of medicine N. Engl. J. Med. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. 615-20 Cytomegalovirus retinitis, a sight-threatening infection associated (...) with the acquired immunodeficiency syndrome (AIDS), currently requires lifelong intravenous treatment. An effective oral treatment would be an important advance. We compared oral with intravenous ganciclovir in an open-label, randomized study in patients with AIDS and newly diagnosed, stable cytomegalovirus retinitis (the disease was stabilized by three weeks of treatment with intravenous ganciclovir). Sixty subjects were randomly assigned to maintenance therapy with intravenous ganciclovir at a dose of 5 mg per kilogram of body weight

NEJM1995

522. National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995

National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995 WHO IRIS: National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995 Browse Related links Files in This Item: File Description Size Format 10.34 MB Adobe PDF Title: National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995 Authors: Issue Date: 1995 Publisher: World Health Organization

WHO1995

523. Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994

Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994 WHO IRIS: Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994 Browse Related links Files in This Item: File Description Size Format 469.13 kB Adobe PDF Title: Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994 Authors: Issue Date: 1995 Publisher

WHO1995

524. Risk, knowledge and behaviour: HIV/AIDS education programmes and young people

Risk, knowledge and behaviour: HIV/AIDS education programmes and young people Risk, knowledge and behaviour: HIV/AIDS education programmes and young people Risk, knowledge and behaviour: HIV/AIDS education programmes and young people Oakley A, Fullerton D Authors' objectives The authors had 3 main objectives: (1) to examine the methodologies and findings of research relevant to HIV or AIDS knowledge with particular relevance to young people in the North East Thames Region of the UK; (2 (...) ) to examine the impact of different intervention programmes on knowledge of risk and on behavioural outcomes; and (3) to make recommendations as to the most effective HIV or AIDS education strategies for future implementation within the North East Thames Region of the UK. Searching Social Science Citation Index on BIDS, MEDLINE, PsycLIT, ERIC, the Health Education Authority's Unicorn database (internal library management system) and the National HIV/AIDS Prevention Information Service database were

DARE.1994

525. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/micro1iters in 5 European countries

Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/micro1iters in 5 European countries Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/micro1iters in 5 European countries Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/micro1iters in 5 European countries Simpson K (...) , Hatziandreu E J, Andersson F, Shakespeare A, Oleksy I, Tosteson A N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Antiviral treatment with Zalcitabine plus Zidovudine for AIDS. Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.1994

526. Megestrol acetate in patients with AIDS and cachexia.

Megestrol acetate in patients with AIDS and cachexia. Megestrol acetate in patients wit... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1994 ) Volume: 121 , Issue: 6 , Pages: 400-408 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To study the effects of a megestrol acetate liquid formulation (800 mg/d) on body weight, body composition, caloric intake, and mental (...) outlook in patients with the acquired immunodeficiency syndrome (AIDS) who had cachexia. DESIGN: Twelve-week, multicenter, randomized, double-blind, placebo-controlled trial. SETTING: Multiple clinical centers. PATIENTS: 100 patients with AIDS who had weight loss of 10% or more of ideal body weight were randomly assigned to placebo (n = 48) or megestrol acetate (n = 52). MEASUREMENTS: Caloric intake, body weight, body composition, and sense of well-being. RESULTS: Most patients receiving megestrol

Annals of Internal Medicine1994

527. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group.

Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. 7906386 1994 03 24 1994 03 24 2013 11 21 0028-4793 330 11 1994 Mar 17 The New England journal of medicine N. Engl. J. Med. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. 738-43 Zidovudine therapy is recommended for asymptomatic (...) patients infected with the human immunodeficiency virus (HIV) who have fewer than 500 CD4+ cells per cubic millimeter. An analysis of the quality of life associated with therapy that integrated both the effects of adverse events and the benefits of delayed disease progression might influence this recommendation. We applied a survival analysis adjusted for the quality of life to data from a randomized trial conducted by the AIDS Clinical Trials Group. The trial compared treatment with 500 mg

NEJM1994

528. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. 7906384 1994 03 21 1994 03 21 2013 11 21 0028-4793 330 10 1994 Mar 10 The New England journal of medicine N. Engl. J. Med. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs (...) for Clinical Research on AIDS. 657-62 Both didanosine and zalcitabine are commonly used to treat patients with human immunodeficiency virus (HIV) infection who cannot tolerate zidovudine treatment or who have had disease progression despite it. The relative efficacy and safety of these second-line therapies are not well defined. In this multicenter, open-label trial we randomly assigned 467 patients who previously received zidovudine and had 300 or fewer CD4 cells per cubic millimeter or a diagnosis

NEJM1994

529. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. 7909866 1994 06 07 1994 06 07 2015 06 16 0140-6736 343 8907 1994 May 14 Lancet (London, England) Lancet Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. 1177-83 Over the past decade various clinical trials have used monoclonal antibodies as therapeutic agents

Lancet1994

530. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.

The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. 7913730 1994 08 19 1994 08 19 2016 10 17 0098-7484 272 6 1994 Aug 10 JAMA JAMA The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. 437-42 To determine the durability of zidovudine-induced delay in clinical progression of asymptomatic (...) human immunodeficiency virus (HIV) disease and to assess the relationship between this effect and the entry CD4+ cell count. Extended follow-up data from subjects participating in protocol 019 of the AIDS [acquired immunodeficiency syndrome] Clinical Trials Group were examined. Subjects were offered a total daily dose of 500 mg of open-label zidovudine after the unblinding of the original randomized trial in 1989. Original treatment groups included placebo, 500 mg of zidovudine, or 1500 mg of zidovudine daily in divided

JAMA1994

531. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. 7913731 1994 08 19 1994 08 19 2016 10 17 0098-7484 272 6 1994 Aug 10 JAMA JAMA Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. 475-80 To evaluate the safety and immunogenicity of the MN strain of recombinant gp120 (...) (MN rgp120) as a vaccine prototype to prevent human immunodeficiency virus (HIV). Double-blind, randomized, placebo-controlled study with subjects vaccinated at 0, 4, 24, and 48 weeks and followed up through 64 weeks. The AIDS Vaccine Evaluation Units in St Louis, Mo, Nashville, Tenn, and Rochester, NY, conducted the clinical study. Laboratory studies were conducted at Duke University, Raleigh, NC; data analysis was done by the Data Coordinating and Analysis Center at the EMMES Corporation

JAMA1994

532. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 7935654 1994 11 03 1994 11 03 2013 11 21 0028-4793 331 18 1994 Nov 03 The New England journal of medicine N. Engl. J. Med. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1173-80 Maternal-infant

NEJM1994

533. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.

A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. 7935655 1994 11 03 1994 11 03 2013 11 21 0028-4793 331 18 1994 Nov 03 The New England journal of medicine N. Engl. J. Med. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced (...) human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. 1181-7 Serious bacterial infections are common in children infected with the human immunodeficiency virus (HIV). Studies performed before zidovudine became standard therapy found that intravenous immune globulin decreases the number of serious bacterial infections in these children. We designed a multicenter study to evaluate the efficacy of intravenous immune globulin in children with advanced HIV infection who were receiving zidovudine

NEJM1994

534. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. 8479489 1993 05 27 1993 05 27 2015 11 19 0028-4793 328 21 1993 May 27 The New England journal of medicine N. Engl. J. Med. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. 1521-7 Both trimethoprim-sulfamethoxazole and pentamidine are effective as treatments for Pneumocystis carinii (...) pneumonia, but adverse effects frequently limit their use. Atovaquone (566C80) is a new hydroxynaphthoquinone with activity against P. carinii. We conducted a double-blind, multicenter study in patients with the acquired immunodeficiency syndrome and mild or moderately severe P. carinii pneumonia. They were randomly assigned to 21 days of orally administered treatment three times daily with either atovaquone (750 mg) or trimethoprim (320 mg) plus sulfamethoxazole (1600 mg). Of the 322 patients

NEJM1993

535. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. 8179648 1993 09 21 1993 09 21 2013 11 21 0028-4793 329 12 1993 Sep 16 The New England journal of medicine N. Engl. J. Med. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. 828-33 Disseminated Mycobacterium avium complex infection eventually develops in most patients with the acquired immunodeficiency syndrome (AIDS). This infection results (...) in substantial morbidity and reduces survival by about six months. We conducted two randomized, double-blind, multicenter trials of daily prophylactic treatment with either rifabutin (300 mg) or placebo. All the patients had AIDS and CD4 cell counts < or = 200 per cubic millimeter. The primary end point was M. avium complex bacteremia as assessed monthly by blood culture. The secondary end points were signs and symptoms associated with disseminated M. avium complex infection, adverse events, hospitalization

NEJM1993

536. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. 1353607 1992 09 02 1992 09 02 2013 11 21 0028-4793 327 9 1992 Aug 27 The New England journal of medicine N. Engl. J. Med. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. 581-7 Although zidovudine is effective in patients (...) with human immunodeficiency virus (HIV) infection, its efficacy may decline with prolonged use. Didanosine is another inhibitor of HIV reverse transcriptase. We evaluated the effectiveness of changing anti-HIV treatment from zidovudine to didanosine. This multicenter, double-blind study involved 913 patients who had tolerated zidovudine for at least 16 weeks. The patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex with less than or equal to 300 CD4 cells per cubic milliliter, or asymptomatic HIV

NEJM1992

537. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. 1360145 1992 12 29 1992 12 29 2015 11 19 0028-4793 327 26 1992 Dec 24 The New England journal of medicine N. Engl. J. Med. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia (...) in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. 1836-41 Primary prophylaxis against Pneumocystis carinii pneumonia (PCP) is recommended for patients with human immunodeficiency virus (HIV) infection if their CD4 cell counts are below 200 per cubic millimeter (0.2 x 10(9) per liter). Either aerosolized pentamidine or trimethoprim-sulfamethoxazole (co-trimoxazole) is commonly prescribed for prophylaxis, but the relative efficacy and toxicity of these agents

NEJM1992

538. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. 1448121 1992 12 29 1992 12 29 2015 11 19 0028-4793 327 26 1992 Dec 24 The New England journal of medicine N. Engl. J. Med. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia (...) in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. 1842-8 Pneumocystis carinii pneumonia (PCP) continues to be the most common index diagnosis in the acquired immunodeficiency syndrome (AIDS), but it is not clear which of several available agents is the most effective in preventing a recurrence of PCP. We conducted a comparative, open-label trial in 310 adults with AIDS who had recently recovered from an initial episode of PCP and had no treatment-limiting

NEJM1992

539. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group.

Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. 1346505 1992 03 09 1992 03 09 2013 11 21 0959-8138 304 6818 1992 Jan 04 BMJ (Clinical research ed.) BMJ Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. 13-7 To compare the efficacy and side effects of 400 mg, 800 mg, and 1200 mg zidovudine daily in patients with AIDS or (...) advanced HIV infection. Randomised, double blind, parallel group multicentre study. Hospital departments of infectious diseases and dermatology in Denmark, Sweden, Norway, Finland, and Iceland. 474 patients: 126 (27%) with AIDS; 248 (52%) with HIV related symptoms; 100 (21%) with low CD4+ cell counts. Zidovudine 400 mg (160 patients), 800 mg (158), or 1200 mg (156) daily. All patients received one capsule from each of three bottles four times daily. Survival; incidence of new HIV related events; CD4

BMJ1992 Full Text: Link to full Text with Trip Pro

540. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. 1727236 1992 01 10 1992 01 10 2013 11 21 0028-4793 326 2 1992 Jan 09 The New England journal of medicine N. Engl. J. Med. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. 83-9 Intravenous (...) amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS). Fluconazole, an oral triazole agent, represents a promising new approach to the treatment of cryptococcal disease. In a randomized multicenter trial, we compared intravenous amphotericin B with oral fluconazole as primary therapy for AIDS-associated acute cryptococcal meningitis. Eligible patients, in all of whom the diagnosis had been

NEJM1992